In the era of comparative and adjunctive trials in reperfusion therapy, the 
As we move into the era of comparative and adjunctive trials in reperfusion therapy, the time has come to reassess the adequacy of end points used to evaluate therapeutic efficacy. Although mortality reduction has been regarded as the "gold standard" for evaluating therapeutic efficacy, other end points have been advocated for a variety of reasons. The huge sample size required to demonstrate a survival advantage (10-20,000 patients)1'2 is relatively prohibitive, given the large number of pharmacological and mechanical strategies that will be available in the near future. The funds and patient numbers to support multiple "megatrials" are simply not available.
Given the lack of feasibility of a megatrial to answer each question, the case for alternative end points can be made for two reasons. First, a surrogate end point can be sought to substitute for mortality. Such an end point would need to be closely correlated with the actual end point of interest (the risk of death) and easily measured in most patients, so that the required sample size to demonstrate a difference would be reduced. Second, treatments might be beneficial through their impact on clinical outcomes other than mortality such as heart failure, reocclu-sion, stroke, or cost. These end points are not truly surrogates but represent alternative end points of importance to the patient and physician for which particular adjunctive therapies may lead to clinically relevant advantages.
Norris and White3 have argued that left ventricular function should be regarded as the preferred surrogate end point. Left ventricular ejection fraction, one measure of left ventricular function, is a continuous measure that allows demonstration of treatment effects with far fewer patients compared with the binary outcome of survival. Furthermore, the pathophysiological rationale for reperfusion therapy is the reduction of infarct size with resultant preservation of left ventricular function; thus, ejection fraction may parallel vessel patency while simultaneously reflecting improved survival. Previous studies have demonstrated the important prognostic implication of ejection fraction after myocardial infarction and the correlation with quality of life.4 Indeed, in 1987, the US Food and Drug Administration set a precedent and approved the commercial release of tissuetype plasminogen activator (t-PA) on the basis of its effects on ejection fraction in addition to establishment of infarct vessel patency and a modest reduction of heart failure.5
In spite of this precedent and the traditional high regard for ejection fraction as the most important postinfarction prognostic marker, we believe that this measure of cardiac function should no longer be considered as the major end point of comparative randomized trials of thrombolytics or adjunctive agents for myocardial reperfusion. Table 1 summarizes the multiple problems associated with relying on ejection fraction in this manner. 
Pathophysiology
The pathophysiological rationale for using ejection fraction as a surrogate end point is clear; that is, reperfusion salvages myocardium, thereby improving ejection fraction. In prethrombolytic era studies, ejection fraction was the most powerful prognostic factor. In general, however, the correlation between ejection fraction and survival in reperfusion trials has been weaker than expected.14,15 This discrepancy was first noted in the Western Washington Intracoronary Streptokinase Trial.16 In this study, the infarct vessel patency status, rather than ejection fraction, was the principal determinant of survival. Van de Werf'4 noted pronounced discordance between ejection fraction and mortality in the European Cooperative t-PA placebo-controlled trial. Many trials comparing thrombolytic therapy with placebo have shown survival benefits that far exceeded differences in ejection fraction, whereas others have shown no survival benefit or paradoxically worse survival, despite improvement in ejection fraction ( Figure 1 ). Although none of these trials was designed to detect mortality differences, the lack of or negative relation between improved survival and improved ejection fraction in these trials raises the issue of how closely ejection fraction measurements reflect the full benefit of reperfusion.
Despite the clearcut relation between time to treatment and mortality reduction with reperfusion therapy, the evidence that patients treated early have dramatic recovery of left ventricular ejection fraction is contradictory. In more than 300 paired left ventriculograms, we could demonstrate no relation between time to treatment and recovery of left ventricular function. 17 Table 2 , the ejection fraction for all reperfusion strategies, whether by comparative thrombolysis,7-11 thrombolysis and angioplasty versus thrombolysis alone,6,8,12,24-26 or adjunctive pharmacotherapies,27-30 has tended to approximate 50%. No significant differences in ejection fraction between therapies have been found in these 13 trials ( Table 2 ).
The SD of ejection fraction in most studies has been approximately 12%. To detect a 4% improvement in ejection fraction, 154 patients with a quantifiable end point in each treatment group would be required for a one-tailed test or 192 patients in each group would be required for a two-tailed test. A smaller number of patients would be necessary to detect a substantial 7% improvement (50 patients each group, one-tailed, or 64 patients each group, two-tailed). Derived from these 13 trials (Table 2) , the 50% rule suggests that any population studied in a reperfusion trial given current inclusion and exclusion criteria is likely to have relatively well-preserved ejection fraction. This outcome emanates to a large extent from the selection of low-risk patients (younger with absence of cardiogenic shock) for trials of thrombolytic therapy and from the missing-value problem already discussed. Furthermore, the ability of the noninfarct zone to compensate and maintain the global ejection fraction31 further limits the use of ejection fraction as a measure of treatment benefit. Three approaches can be taken to combining multiple end points. In one approach, commonly used in studies of outcome after medical or surgical therapy for coronary disease, the occurrence of any single outcome can be treated as the end point. 34 The results are then expressed in terms of freedom from any event. Although this method has the advantage of simplicity and lends itself to analysis of timerelated outcomes, it suffers from the equal weight given to end points of markedly different importance. If the relative impact of each end point can be agreed on, the end points can be placed on a scale with a numerical assignment or "weight." Although this method has the potential for great precision, clinicians and patients can seldom agree about the appropriate weight for each end point with enough certainty to make the results interpretable. The approach we prefer is to rank the end points in order of importance.
We conducted a survey of 407 cardiologists at the 1989 American Heart Association meetings to examine whether a consensus existed regarding the most important end points that might be affected by a reperfusion strategy. 35 Of the cardiologists, 28% were academically based, 38% were in practice, and 35% were in training or had a combined classification. For each clinical end point after myocardial reperfusion strategies, the cardiologist was asked to score each outcome on a scale of 0 to 10, with 10 signifying the most serious negative end point. In Table 3 , results of this survey are presented according to the actual scores assigned by each cardiologist and also according to a simple rank-ordering of these scores. The ranking was constructed by assigning a rank of 1 to the outcome scores that were the highest (worst), a value of 2 to the outcome that scored second highest, and so on. Results for the ordinal ranking and mean score reflected concordance with the following five tiers of negative outcomes: 1) death; 2) hemorrhagic stroke; 3) thromboembolic stroke, poor ejection fraction, or reinfarction; 4) heart failure; and 5) serious recurrent ischemia without reinfarction.
The ranking from these outcomes can be used as a single ordered end point, which should be available on every patient in a clinical trial. The comparison of this ordinal ranking can be performed by using an ordinal logistic model.36 This model predicts the ordinal rank of the end point as a function of treatment group. The outcomes are dependent on simple clinical measurements rather than technical studies fraught with the inadequacy rates previously discussed. Importantly, however, when such a combined end point is used, not only should the rankings be presented, but the individual clinical outcomes should be displayed. This approach of displaying each clinical end point has been termed the "Consumer Reports approach" because it allows the patient or physician with particular preferences to examine the data and make individual choices.
An example of this approach from a hypothetical clinical trial constructed from the TAMI database is given in Table 4 . These data were obtained from two clinical trials done by the TAMI Study Group. In TAMI 2, 112 patients received combined t-PA and urokinase.37 These patients had a lower rate of death, emergency revascularization, and recurrent angina compared with the 175 patients treated with t-PA monotherapy (TAMI-3). 9 The changes in ejection fraction and the predischarge fraction values were (10) 34 (19) As the number of possible therapeutic combinations continues to multiply, approaches using nonfatal end points will become increasingly important. The 
